4//SEC Filing
Colowick Alan 4
Accession 0001209191-20-052228
CIK 0001510487other
Filed
Sep 27, 8:00 PM ET
Accepted
Sep 28, 5:21 PM ET
Size
12.8 KB
Accession
0001209191-20-052228
Insider Transaction Report
Form 4
Colowick Alan
Director
Transactions
- Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−20,475→ 0 totalExercise: $17.00Exp: 2028-09-12→ Common Stock (20,475 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−47,724→ 0 totalExercise: $4.54Exp: 2027-06-26→ Common Stock (47,724 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−10,240→ 0 totalExercise: $31.77Exp: 2029-06-10→ Common Stock (10,240 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−10,240→ 0 totalExercise: $62.66Exp: 2030-06-03→ Common Stock (10,240 underlying)
Footnotes (1)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Documents
Issuer
Principia Biopharma Inc.
CIK 0001510487
Entity typeother
Related Parties
1- filerCIK 0001316163
Filing Metadata
- Form type
- 4
- Filed
- Sep 27, 8:00 PM ET
- Accepted
- Sep 28, 5:21 PM ET
- Size
- 12.8 KB